Advanced Biotherapy, Inc. is a corporation organized and existing under the laws of the State of Delaware, headquartered in Chicago, Illinois.
Prior to its debt restructure and equity placement in 2006, our Company focused on the development of biologic therapeutic antibodies for treating a range of autoimmune diseases based on an anti-cytokine platform technology. Our activities have consisted primarily of research, development and non-United States investigational human clinical trials. Such development stage activities have resulted in an accumulated deficit of $20,769,079 at December 31, 2006. Based upon our historical activities, we are a development stage biotechnology company holding patents based on the anti-cytokine platform. Management currently does not plan to continue the Company's research and development projects or to pursue new patent applications. (See the section captioned "BUSINESS OBJECTIVES" below.)
Our autoimmune disease technology focuses on an anti-cytokine platform. The Company's primary cytokine target has been interferon-gamma. Cytokines are soluble components of the immune system that are largely responsible for regulating the immune response. When overproduced, as in certain autoimmune diseases, interferons and cytokines can lead to immune system disturbance and inflammation resulting in localized tissue damage and pathology seen in autoimmune diseases (ADs). To date, the Company has not achieved its plans to enter into out-licensing agreements with pharmaceutical companies that seek to use the Company's patents to develop biologic drugs designed to reduce the levels of certain cytokines that may effectively treat a range of autoimmune diseases.
Prior to its debt restructure and equity placement in 2006, our Company focused on the development of biologic therapeutic antibodies for treating a range of autoimmune diseases based on an anti-cytokine platform technology. Our activities have consisted primarily of research, development and non-United States investigational human clinical trials. Such development stage activities have resulted in an accumulated deficit of $20,769,079 at December 31, 2006. Based upon our historical activities, we are a development stage biotechnology company holding patents based on the anti-cytokine platform. Management currently does not plan to continue the Company's research and development projects or to pursue new patent applications. (See the section captioned "BUSINESS OBJECTIVES" below.)
Our autoimmune disease technology focuses on an anti-cytokine platform. The Company's primary cytokine target has been interferon-gamma. Cytokines are soluble components of the immune system that are largely responsible for regulating the immune response. When overproduced, as in certain autoimmune diseases, interferons and cytokines can lead to immune system disturbance and inflammation resulting in localized tissue damage and pathology seen in autoimmune diseases (ADs). To date, the Company has not achieved its plans to enter into out-licensing agreements with pharmaceutical companies that seek to use the Company's patents to develop biologic drugs designed to reduce the levels of certain cytokines that may effectively treat a range of autoimmune diseases.
